136 related articles for article (PubMed ID: 26117054)
1. [Progress of Study on Cytokines in Myeloproliferative Neoplasms].
Sun CC; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):878-82. PubMed ID: 26117054
[TBL] [Abstract][Full Text] [Related]
2. [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].
He ZP; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):589-594. PubMed ID: 29665937
[TBL] [Abstract][Full Text] [Related]
3. Genetic basis of MPN: Beyond JAK2-V617F.
Them NC; Kralovics R
Curr Hematol Malig Rep; 2013 Dec; 8(4):299-306. PubMed ID: 24190690
[TBL] [Abstract][Full Text] [Related]
4. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
Liu L; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
[TBL] [Abstract][Full Text] [Related]
5. Mutations in myeloproliferative neoplasms - their significance and clinical use.
Schischlik F; Kralovics R
Expert Rev Hematol; 2017 Nov; 10(11):961-973. PubMed ID: 28914569
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment.
Vakil E; Tefferi A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Rosti V; Campanelli R; Massa M; Viarengo G; Villani L; Poletto V; Bonetti E; Catarsi P; Magrini U; Grolla AA; Travelli C; Genazzani AA; Barosi G
Am J Hematol; 2016 Jul; 91(7):709-13. PubMed ID: 27074203
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.
Hoermann G; Greiner G; Valent P
Mediators Inflamm; 2015; 2015():869242. PubMed ID: 26543328
[TBL] [Abstract][Full Text] [Related]
9. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
11. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
12. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
13. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
14. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
15. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
16. [Current problems in the diagnosis of Philadelphia-negative myeloproliferative neoplasms in Japan].
Shirane S; Araki M; Morishita S; Edahiro Y; Ohsaka A; Komatsu N
Rinsho Ketsueki; 2015 Jul; 56(7):877-82. PubMed ID: 26251152
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]